Stock Report

Dr Reddy's is the First Participant in United States Pharmacopoeia's New Pharmaceutical Ingredient Verification Programme



Posted On : 2007-04-17 03:45:07( TIMEZONE : IST )

Dr Reddy's is the First Participant in United States Pharmacopoeia's New Pharmaceutical Ingredient Verification Programme

Dr Reddys Laboratories Ltd on April 17, 2007 has announced that it has signed on as the first participant in United States Pharmacopoeia's (USP) Pharmaceutical Ingredient Verification Programme.

"We look forward to participating in this programme so that we can show manufacturers, regulatory authorities and consumers our dedication to producing pharmaceutical ingredients that are of consistently high quality," said Satish Reddy, Chief Operating Officer and Managing Director of the Company.

USP created the Pharmaceutical Ingredient Verification Programme in response to increasing concerns throughout the pharmaceutical industry about the quality and consistency of pharmaceutical ingredients. The programme enables manufacturers to show the quality and integrity of their ingredients with a recognizable 'USP Verified' mark.

As a participant in the Pharmaceutical Ingredient Verification Programme, the Company will submit ingredients to USP's verification process, which includes:

- Evaluation of an ingredient manufacturer's quality systems through an audit for compliance with Good Manufacturing Practices (GMPs)

- Review of manufacturing and quality control documents for the ingredients

- Laboratory testing of ingredient samples from USP-selected lots for compliance with USP's FDA-enforceable standards for purity, potency and quality

- Post-verification surveillance testing of ingredients bearing the USP Verified mark

Once each ingredient passes the verification process, the Company will receive a Certificate of Standards Compliance. They will be permitted to post the 'USP Verified' mark on the shipping container, and certificate of analysis demonstrating that it meets USP's world-class quality standards.

Source : Equity Bulls

Keywords